CDK4/6-IN-10

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK4/6-IN-10 

CDK4/6-IN-10 是一种有效的、选择性的和具有口服活性的 CDK4 和 CDK6 抑制剂，其 IC50 值分别为 22 nM 和 10 nM。CDK4/6-IN-10 显示出抗肿瘤活性。CDK4/6-IN-10 具有研究多发性骨髓瘤 (MM) 的潜力。

CDK4/6-IN-10

CDK4/6-IN-10 Chemical Structure

CAS No. : 2688098-11-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK4/6-IN-10 is a potent, selective and orally active CDK4 and CDK6 inhibitor with IC50s of 22 nM and 10 nM, respectively. CDK4/6-IN-10 shows antitumor activity. CDK4/6-IN-10 has the potential for the research of Multiple myeloma (MM)[1].

IC50 & Target[1]

CDK4

22 nM (IC50)

CDK6/cyclinD1

10 nM (IC50)

体外研究
(In Vitro)

CDK4/6-IN-10 (compouns 32) (1 µM) shows kinase selectivity with IC50s of 22 nM and 10 nM for CDK4 and CDK6, respectively[1].
CDK4/6-IN-10 (72 h) shows antiproliferative activity (GI50s of 2.028, 5.802, 2.286, 2.238, 1.526, 11.381 µM for RPMI-8226, U266, K562, HL-60, 22RV1, HEK-293 cells, respectively)[1].
CDK4/6-IN-10 (0, 1.5, 3, 6 µM, 24 h) induces cell cycle arrest at the G1 phase in a concentration-dependent manner[1].
CDK4/6-IN-10 ( 0, 1, 2, 3 µM, 24 h) induces apoptosis of RPMI-8226 cells in a concentration-dependent manner[1].
CDK4/6-IN-10 (0, 1.5, 3, 6 µM, 24 h) reduces the CDK4/6 activity by decreases the expression level of p-RB, c-MYC and BCL-2[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: RPMI-8226, U266, K562, HL-60, 22RV1, HEK-293 cells
Concentration:
Incubation Time: 72 h
Result: Shows antiproliferative activity (GI50s of 2.028, 5.802, 2.286, 2.238, 1.526, 11.381 µM for RPMI-8226, U266, K562, HL-60, 22RV1, HEK-293 cells, respectively).

Cell Cycle Analysis[1]

Cell Line: RPMI-8226 cells
Concentration: 0, 1.5, 3, 6 µM
Incubation Time: 24 h
Result: Cells were arrested at the G1 phase in a concentration-dependent manner.

Apoptosis Analysis[1]

Cell Line: RPMI-8226 cells
Concentration: 0, 1.5, 3, 6 µM
Incubation Time: 24 h
Result: Reduced the CD4/K activity by decreased the expression level of p-RB, c-MYC and BCL-2.

体内研究
(In Vivo)

CDK4/6-IN-10 (1000, 5000, 10000 mg/kg; p.o.) shows safety profile with LD50 much higher than 10,000 mg/kg[1].
CDK4/6-IN-10 (10 mg/kg; p.o.) shows oral bioavailability (F=51%) in SD rats[1].
CDK4/6-IN-10 (100, 200 mg/kg; p.o., once a day for 19 days) shows antitumor potency and favorable safety profile[1].
Pharmacokinetic Parameters of CDK4/6-IN-10 in SpragueeDawley rats[1].

Compd Admin. Cmax (ng/mL) AUC0-t (h·ng/mL) MRT0-t (h) Tmax (h) t1/2 (h) CL (mL/h/kg) F (%)
32 i.v. 355 960 5.9 0.033 8.9 641 –
p.o. 257 4,878 12.8 10.7 >24 524 51

SpragueeDawley rats, 10 mg/kg, p.o.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: ICR mice[1]
Dosage: 1000, 5000, 10000 mg/kg
Administration: p.o.
Result: Showed safety profile with LD50 much higher than 10,000 mg/kg.
Animal Model: SpragueeDawley rats[1]
Dosage: 10 mg/kg
Administration: p.o.
Result: Showed oral bioavailability (F=51%).
Animal Model: BALB/c nude mice (6-8 weeks) (MM xenograft model)[1]
Dosage: 100, 200 mg/kg
Administration: p.o., once a day, 19 days
Result: Showed antitumor potency and favorable safety profile.

分子量

418.47

Formula

C22H23FN8
CAS 号

2688098-11-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Yuan K, et al. Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma. Eur J Med Chem. 2022; 228:114024.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务